Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Vavalà T[au]:

Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? Buffoni L et al. Curr Treat Options Oncol. (2016)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma. Vavalà T et al. Clin Pharmacol. (2017)

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Konduri K et al. Cancer Discov. (2016)

Search results

Items: 22

1.

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.

Abbate MI, Cortinovis DL, Tiseo M, Vavalà T, Cerea G, Toschi L, Canova S, Colonese F, Bidoli P.

Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25.

PMID:
30681378
2.

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.

Turkaj A, Morelli AM, Vavalà T, Novello S.

Front Oncol. 2018 Jul 27;8:278. doi: 10.3389/fonc.2018.00278. eCollection 2018. Review.

3.

Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy.

Vavalà T, Novello S.

Ther Adv Med Oncol. 2018 Aug 3;10:1758835918789364. doi: 10.1177/1758835918789364. eCollection 2018. Review.

4.

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

Vavalà T.

Clin Pharmacol. 2017 Nov 27;9:147-157. doi: 10.2147/CPAA.S112715. eCollection 2017. Review.

5.

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S.

Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1.

PMID:
28645631
6.

Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?

Buffoni L, Vavalà T, Novello S.

Curr Treat Options Oncol. 2016 Oct;17(10):54. doi: 10.1007/s11864-016-0429-x. Review.

PMID:
27523606
7.

Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.

Vavalà T, Monica V, Lo Iacono M, Mele T, Busso S, Righi L, Papotti M, Scagliotti GV, Novello S.

Lung Cancer. 2017 May;107:84-90. doi: 10.1016/j.lungcan.2016.05.021. Epub 2016 May 31.

PMID:
27346245
8.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

9.

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S.

Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26.

10.

Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study.

Vatrano S, Righi L, Vavalá T, Rapa I, Busso M, Izzo S, Cappia S, Veltri A, Papotti M, Scagliotti GV, Novello S.

Target Oncol. 2016 Apr;11(2):157-66. doi: 10.1007/s11523-015-0383-8.

11.

Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.

Pilotto S, Sperduti I, Novello S, Peretti U, Milella M, Facciolo F, Vari S, Leuzzi G, Vavalà T, Marchetti A, Mucilli F, Crinò L, Puma F, Kinspergher S, Santo A, Carbognin L, Brunelli M, Chilosi M, Scarpa A, Tortora G, Bria E.

J Thorac Oncol. 2015 Sep;10(9):1341-1348. doi: 10.1097/JTO.0000000000000628.

12.

An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.

Pilotto S, Novello S, Peretti U, Kinspergher S, Ciuffreda L, Milella M, Carbognin L, Vavalà T, Ferrara R, Caccese M, Tortora G, Bria E.

Expert Opin Investig Drugs. 2015;24(9):1143-61. doi: 10.1517/13543784.2015.1056341. Epub 2015 Jun 12. Review.

PMID:
26065529
13.

Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era.

Busso M, Sardo D, Garetto I, Righi L, Libero G, Vavalà T, Ardissone F, Novello S, Papotti M, Veltri A.

Radiol Med. 2015 Nov;120(11):1024-30. doi: 10.1007/s11547-015-0538-9. Epub 2015 May 1.

PMID:
25930161
14.

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

Bria E, Pilotto S, Amato E, Fassan M, Novello S, Peretti U, Vavalà T, Kinspergher S, Righi L, Santo A, Brunelli M, Corbo V, Giglioli E, Sperduti I, Milella M, Chilosi M, Scarpa A, Tortora G.

Oncotarget. 2015 May 20;6(14):12783-95.

15.

Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?

Rossi G, Ragazzi M, Tamagnini I, Mengoli MC, Vincenzi G, Barbieri F, Piccioli S, Bisagni A, Vavala T, Righi L, Novello S, Gelsomino F, Tiseo M.

Curr Drug Targets. 2017;18(1):13-26. Review.

16.

Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome.

Righi L, Vavalà T, Rapa I, Vatrano S, Giorcelli J, Rossi G, Capelletto E, Novello S, Scagliotti GV, Papotti M.

J Thorac Oncol. 2014 Oct;9(10):1540-6. doi: 10.1097/JTO.0000000000000271.

17.

ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.

Lo Iacono M, Monica V, Vavalà T, Gisabella M, Saviozzi S, Bracco E, Novello S, Papotti M, Scagliotti GV.

Int J Cancer. 2015 Jun 1;136(11):2598-609. doi: 10.1002/ijc.29302. Epub 2014 Nov 12.

18.

Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.

Novello S, Vavalà T, Levra MG, Solitro F, Pelosi E, Veltri A, Scagliotti GV.

Clin Lung Cancer. 2013 May;14(3):230-7. doi: 10.1016/j.cllc.2012.10.004. Epub 2012 Dec 29.

PMID:
23276821
19.

Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence.

Novello S, Giaj Levra M, Vavalà T.

Crit Rev Oncol Hematol. 2012 Aug;83(2):208-15. doi: 10.1016/j.critrevonc.2011.09.009. Epub 2011 Nov 6. Review.

PMID:
22062925
20.

Maintenance therapy in NSCLC: why? To whom? Which agent?

Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E.

J Exp Clin Cancer Res. 2011 May 6;30:50. doi: 10.1186/1756-9966-30-50. Review.

21.

Lung cancer and women.

Novello S, Vavalà T.

Future Oncol. 2008 Oct;4(5):705-16. doi: 10.2217/14796694.4.5.705. Review.

PMID:
18922127
22.

[Gastrointestinal opportunistic infections and human immunodeficiency virus (HIV). Case report].

Stagnitti F, Vavalà T, Corelli S, Gammardella P, Martellucci A, Tartaglione L, Di Pucchio E, Calì B, Toccaceli S, Spaziani E, Casciaro GE, Marenga G, Soda G.

G Chir. 2007 Jun-Jul;28(6-7):270-3. Italian.

PMID:
17626771

Supplemental Content

Loading ...
Support Center